IGMS241220P40000
- 0.00
- 0.000.00%
IGM Biosciences Newsroom
Stifel Maintains IGM Biosciences(IGMS.US) With Buy Rating, Raises Target Price to $27
Express News | IGM Biosciences Inc : Stifel Raises Target Price to $27 From $25
RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)
Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development
IGM Biosciences Shifts Focus to Autoimmunity
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates
IGM Biosciences | 8-K: IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | IGM Biosciences Inc: Cash Runway Expected to Fund Operations Into 2027
Express News | IGM Biosciences Q3 Basic EPS USD -1.01
Express News | IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | IGM Biosciences Q3 Collaboration Revenue USD 516 Thousand
IGM Biosciences | 10-Q: Q3 2024 Earnings Report
Express News | IGM Biosciences: To Incur Restructuring Charges Between $11.7 Mln and $14.4 Mln
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Despite Shrinking by US$96m in the Past Week, IGM Biosciences (NASDAQ:IGMS) Shareholders Are Still up 232% Over 1 Year
IGM Biosciences to Present at Three Upcoming Investor Conferences
Dow Dips Over 300 Points; Viad Shares Spike Higher
IGM Biosciences Is Maintained at Outperform by RBC Capital
RBC Capital Maintains IGM Biosciences(IGMS.US) With Buy Rating, Raises Target Price to $20
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), IGM Biosciences (IGMS)